UroGen Pharma Ltd (URGN)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

9 HA'TA'ASIYA ST RA'ANANA, ISRAEL 4365007

UroGen Pharma Ltd. operates as a clinical stage biopharmaceutical company. The Company focuses on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology.

Data as of 2021-05-08 11:50:13 -0400
Market Cap406.283 Million Shares Outstanding22.299 Million Avg 30-day Volume115.483 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-3.75 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.14182 52-week High/Low30.89 / 17.01 Next Earnings Date Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from URGN instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 2 (0.12%) 2 (0.12%) 0.0%
Funds Holding: 81 78 3.85% 19 (1.14%) 19 (1.18%) 0.0%
13F shares: 14.534 Million 14.958 Million -2.84% 5.375 Million 5.837 Million -7.92%
% Ownership 65.7847 67.7043 -2.84% 24.3273 26.4205 -7.92%
New Positions: 10 3 233.33% 3 1 200.0%
Increased Positions 25 27 -7.41% 7 6 16.67%
Closed Positions 8 7 14.29% 3 2 50.0%
Reduced Positions 26 31 -16.13% 5 9 -44.44%
Total Calls 113.604 Thousand 192.801 Thousand -41.08% 0
Total Puts 275.601 Thousand 257.3 Thousand 7.11% 22.3 Thousand 0
PUT/CALL Ratio 2.43 1.33 82.71% 82.71%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding URGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding URGN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

332 total shares from 2 transactions

Exercise Derivative Conversion (M)

5 Thousand total shares from 4 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SCHOENBERG MARK CHIEF MEDICAL OFFICER

  • Officer
24,632 2021-04-30 9

BELLDEGRUN ARIE

  • Director
245,452 2021-03-24 2

NUSSBAUM RAN

  • Director
1,465,199 2021-03-24 2

BARRETT ELIZABETH A. CHIEF EXECUTIVE OFFICER

  • Officer
0 2021-01-31 4

SMITH JASON DREW GENERAL COUNSEL

  • Officer
0 2021-01-31 4

HENDERSON MOLLY CHIEF FINANCIAL OFFICER

  • Officer
0 2021-01-31 3

PFREUNDSCHUH PETER P. CHIEF FINANCIAL OFFICER

  • Officer
10,405 2020-10-15 4

BUTITTA CYNTHIA M

  • Director
0 2020-06-08 1

HOLDEN STUART

  • Director
0 2020-06-08 1

FALBERG KATHRYN E

  • Director
0 2020-06-08 1

COHEN FRED E

  • Director
0 2020-06-08 1

TOMASELLO SHAWN

  • Director
0 2020-06-08 1

MULLENNIX STEPHEN CHIEF OPERATING OFFICER

  • Officer
10,084 2020-04-26 0

BENTSUR RON CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
38,113 2019-01-01 0

PROQUEST INVESTMENTS IV, L.P.

PROQUEST ASSOCIATES IV LLC

MOORIN JAY

SCHREIBER ALAIN

  • 10% Owner
No longer subject to file 2017-11-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SCHOENBERG MARK - Officer CHIEF MEDICAL OFFICER

2021-05-04 13:58:40 -0400 2021-04-30 S 243 $20.00 d 21,132 direct -3.673 0.0 1 -3.673 2

SCHOENBERG MARK - Officer CHIEF MEDICAL OFFICER

2021-05-04 13:58:40 -0400 2021-04-30 M 500 a 21,375 direct -3.673 0.0 1 -3.673 2

SCHOENBERG MARK - Officer CHIEF MEDICAL OFFICER

2021-05-04 13:58:40 -0400 2021-04-30 M 500 d 3,500 direct

SCHOENBERG MARK - Officer CHIEF MEDICAL OFFICER

2021-04-27 13:44:33 -0400 2021-04-26 S 89 $19.63 d 20,875 direct -0.2865 -7.6886 0.0 1 -7.6886 6

SCHOENBERG MARK - Officer CHIEF MEDICAL OFFICER

2021-04-27 13:44:33 -0400 2021-04-26 M 209 a 20,964 direct -0.2865 -7.6886 0.0 1 -7.6886 6

SCHOENBERG MARK - Officer CHIEF MEDICAL OFFICER

2021-04-27 13:44:33 -0400 2021-04-26 M 209 d 625 direct

BELLDEGRUN ARIE - Director

2021-04-22 17:19:31 -0400 2021-03-24 M 3,241 $5.00 a 245,452 direct 6.3233 -0.8159 6.7823 3 -0.8159 6

NUSSBAUM RAN - Director managing partner of entities affiliated with pontifax management iii g.p. (

2021-04-22 17:18:40 -0400 2021-03-24 M 1,030 $5.00 a 1,465,199 indirect 6.3233 -0.8159 6.7823 3 -0.8159 6

BELLDEGRUN ARIE - Director

2021-04-22 17:19:31 -0400 2021-03-24 M 3,241 d 0 direct

NUSSBAUM RAN - Director by pontifax cayman iii limited partnership

2021-04-22 17:18:40 -0400 2021-03-24 M 1,030 d 0 indirect

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
UROGEN PHARMA LTD URGN 2021-05-11 22:15:03 UTC -0.6466 0.6966 55000
UROGEN PHARMA LTD URGN 2021-05-11 21:45:03 UTC -0.6466 0.6966 55000
UROGEN PHARMA LTD URGN 2021-05-11 21:15:03 UTC -0.6466 0.6966 55000
UROGEN PHARMA LTD URGN 2021-05-11 20:45:03 UTC -0.6465 0.6965 55000
UROGEN PHARMA LTD URGN 2021-05-11 20:15:03 UTC -0.6465 0.6965 55000
UROGEN PHARMA LTD URGN 2021-05-11 19:45:03 UTC -0.6465 0.6965 55000
UROGEN PHARMA LTD URGN 2021-05-11 19:15:02 UTC -0.6465 0.6965 55000
UROGEN PHARMA LTD URGN 2021-05-11 18:45:02 UTC -0.6434 0.6934 55000
UROGEN PHARMA LTD URGN 2021-05-11 18:15:03 UTC -0.6434 0.6934 55000
UROGEN PHARMA LTD URGN 2021-05-11 17:45:03 UTC -0.6434 0.6934 55000
UROGEN PHARMA LTD URGN 2021-05-11 17:15:04 UTC -0.6434 0.6934 55000
UROGEN PHARMA LTD URGN 2021-05-11 16:45:04 UTC -0.6434 0.6934 55000
UROGEN PHARMA LTD URGN 2021-05-11 16:15:04 UTC -0.6434 0.6934 55000
UROGEN PHARMA LTD URGN 2021-05-11 15:45:03 UTC -0.6434 0.6934 55000
UROGEN PHARMA LTD URGN 2021-05-11 15:15:03 UTC -0.6434 0.6934 55000
UROGEN PHARMA LTD URGN 2021-05-11 14:45:03 UTC -0.8255 0.8755 55000
UROGEN PHARMA LTD URGN 2021-05-11 14:15:03 UTC -0.8255 0.8755 55000
UROGEN PHARMA LTD URGN 2021-05-11 13:45:04 UTC -0.8255 0.8755 55000
UROGEN PHARMA LTD URGN 2021-05-11 13:15:04 UTC -0.8255 0.8755 55000
UROGEN PHARMA LTD URGN 2021-05-11 12:45:03 UTC -0.8255 0.8755 55000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Advanced Series Trust- AST Academic Strategies Asset Allocation Portfolio URGN -2600.0 shares, $-46852.0 2020-12-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund URGN -4.0 shares, $-71.36 2020-03-31 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund URGN -900.0 shares, $-17532.0 2021-03-31 N-PORT

Elevate your investments